RenovoRx (NASDAQ:RNXT) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Financial Comparison

EOM Pharmaceuticals (OTCMKTS:IMUC) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Earnings and Valuation

This table compares EOM Pharmaceuticals and RenovoRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceuticals	N/A	N/A	-$1.61 million	N/A	N/A
RenovoRx	N/A	N/A	-$10.23 million	($0.57)	-2.23

Institutional & Insider Ownership

3.1% of RenovoRx shares are held by institutional investors. 3.3% of EOM Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for EOM Pharmaceuticals and RenovoRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceuticals	0	0	0	0	0.00
RenovoRx	0	0	2	0	3.00

RenovoRx has a consensus price target of $6.13, suggesting a potential upside of 382.28%. Given RenovoRx’s stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than EOM Pharmaceuticals.

Volatility and Risk

EOM Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Profitability

This table compares EOM Pharmaceuticals and RenovoRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceuticals	N/A	N/A	N/A
RenovoRx	N/A	-205.96%	-110.01%

Summary

RenovoRx beats EOM Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About EOM Pharmaceuticals

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.